

Gastric, Esophageal, and Gastroesophageal Junction Cancer (Adenocarcinoma) Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: Neoadjuvant/Pre-Op Adjuvant/Post-Op
 1st Line 2nd Line 3rd Line 3rd Line+

ECOG Performance Status: _____ **ICD-10 Code:** _____

Will the patient be undergoing surgery? Yes No

Will the patient be undergoing radiation therapy? Yes No

Primary Therapy | Resectable and Unresectable Disease

- Cisplatin and fluorouracil (5FU)
- Fluorouracil (5FU) and cisplatin with concurrent radiation therapy (RT)
- FLOT:** Fluorouracil (5FU), leucovorin, oxaliplatin, and docetaxel (Taxotere)
- Paclitaxel and carboplatin with concurrent RT*

Post-Operative Treatment

- Fluorouracil (5FU) and leucovorin with concurrent RT

Recurrent/Metastatic or Locally Advanced/Inoperable Disease | HER2 Negative | First Line of Therapy (1st Line)

- Cisplatin and fluorouracil (5FU)†
- Fluorouracil (5FU) and irinotecan (Camptosar)
- FLO/FOLFOX:** fluorouracil (5FU), leucovorin, and oxaliplatin
- FLP:** fluorouracil (5FU), leucovorin, and cisplatin

Recurrent/Metastatic or Locally Advanced/Inoperable Disease | HER2 Positive | First Line of Therapy (1st Line)

- Cisplatin, fluorouracil (5FU), and trastuzumab (Herceptin)

Recurrent/Metastatic or Locally Advanced/Inoperable Disease | Second Line of Therapy (2nd Line)

- Irinotecan (Camptosar)
- Paclitaxel

* Limited to esophageal and gastroesophageal junction cancers only

† Limited to gastric tumors only

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.

